A5065029182- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Biosimilars and Bioanalytical Methods
- Ferroptosis and cancer prognosis
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Silicon Carbide Semiconductor Technologies
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Metabolomics and Mass Spectrometry Studies
- Monoclonal and Polyclonal Antibodies Research
- Integrated Circuits and Semiconductor Failure Analysis
- Nanowire Synthesis and Applications
- Synthesis and Biological Evaluation
- Advanced Fluorescence Microscopy Techniques
- Acute Lymphoblastic Leukemia research
- RNA Interference and Gene Delivery
- Advanced Biosensing Techniques and Applications
- Cancer-related molecular mechanisms research
- Sphingolipid Metabolism and Signaling
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Genomics, phytochemicals, and oxidative stress
University of South Florida
2020-2025
Moffitt Cancer Center
2017-2024
Seoul National University
2012-2020
Seoul National University Hospital
2017
Idiopathic pulmonary fibrosis (IPF) is a progressive, eventually fatal disease characterized by of the lung parenchyma and loss function. IPF believed to be caused repetitive alveolar epithelial cell injury dysregulated repair process including uncontrolled proliferation (myo) fibroblasts excessive deposition extracellular matrix proteins in interstitial space; however, pathogenic pathways involved have not been fully elucidated. In this study, we attempted characterize metabolic changes...
Background Co-stimulatory signals regulate the expansion, persistence, and function of chimeric antigen receptor (CAR) T cells. Most studies have focused on co-stimulatory domains CD28 or 4-1BB. CAR cell persistence is enhanced by 4-1BB co-stimulation leading to nuclear factor kappa B (NF-κB) signaling, while resistance exhaustion mutations domain. Methods We hypothesized that a third-generation containing with only PYAP signaling motif (mut06) would provide beneficial aspects both. designed...
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated severe immune-mediated toxicities and inferior responses in 146 DLBCL axicabtagene ciloleucel. develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) ferritin to classify into low-, intermediate-, high-risk groups. observe that the category were more likely grade ≥3 had...
One of the challenges adoptive T-cell therapy is development immune-mediated toxicities including cytokine release syndrome (CRS) and neurotoxicity (NT). We aimed to identify factors that place patients at high risk severe toxicity or treatment-related death in a cohort 75 with large B-cell lymphoma treated standard care CD19 targeted CAR product (axicabtagene ciloleucel).Serum catecholamine levels were measured prior lymphodepleting chemotherapy, on day T infusion daily thereafter while...
Abstract Background Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute coronary syndrome and cardiovascular death occur in 10–15% of patients treated with CAR-T. This study aims to investigate the changes cardiac inflammatory biomarkers CAR-T therapy determine role pro-inflammatory cytokines. Methods In this observational study, ninety...
An obstacle to the development of chimeric antigen receptor (CAR) T cells is limited understanding CAR T-cell biology and mechanisms behind their antitumor activity. We others have shown that CARs with a CD28 costimulatory domain drive high activation, which leads exhaustion shortened persistence. This work led us hypothesize by incorporating null mutations subdomains (YMNM, PRRP, or PYAP), we could optimize costimulation enhance function.
Metabolic rewiring has been recognized as an important feature to the progression of cancer. However, essential components and functions lipid metabolic networks in breast cancer are not fully understood. In this study, we investigated roles altered metabolism malignant phenotype Using a spheroid-induced epithelial-mesenchymal transition (EMT) model, conducted multi-layered lipidomic transcriptomic analysis comprehensively describe lipidome during transformation. A tremendous homeostatic...
To better understand the respiratory lipid phenotypes of asthma, we developed a novel method for profiling bronchoalveolar lavage fluid (BALF) using HPLC-QTOF-MS with an internal spectral library and high-throughput lipid-identifying software. The was applied to BALF from 38 asthmatic patients (18 nonsteroid treated bronchial asthma [NSBA] 20 steroid [SBA]) 13 healthy subjects (NC). We identified 69 lipids, which were categorized into one six classes: lysophosphatidylcholine (LPC),...
The metabolic properties of tumor microenvironment (TME) are dynamically dysregulated to achieve immune escape and promote cancer cell survival. However, in vivo glucose metabolism cells poorly understood their clinical application development a biomarker reflecting functionality is still lacking. Methods: We analyzed RNA-seq fluorodeoxyglucose (FDG) positron emission tomography profiles 63 lung squamous carcinoma (LUSC) specimens correlate FDG uptake, expression transporters (GLUT) by...
CAR-T therapy has led to significant improvements in patient survival. However, a subset of patients experience high-grade toxicities, including cytokine release syndrome (CRS) and immune cell-associated hematologic toxicity (ICAHT). We utilized IL-2Rα knockout mice model toxicities with elevated levels IL6, IFNγ, TNFα increased M1-like macrophages. Onset CRS was accompanied by reduction peripheral blood neutrophils due disruption bone marrow neutrophil homeostasis characterized an increase...
<title>Abstract</title> Chimeric antigen receptor (CAR) T cell therapies have revolutionized B malignancy treatment, but subsets of patients with large lymphoma (LBCL) experience primary resistance or relapse after CAR treatment. To uncover tumor microenvironment (TME)-induced mechanisms, we examined patients’ intratumoral immune infiltrates and observed that elevated levels immunoregulatory macrophages in pre-infusion biopsies are correlated poor clinical responses. cell-produced...
Abstract The immune microenvironment in lung squamous cell carcinoma (LUSC) is not well understood, with interactions between the host system and tumor, as molecular pathogenesis of LUSC, awaiting better characterization. To date, no molecularly targeted agents have been developed for LUSC treatment. Identification predictive prognostic biomarkers could help optimize therapy decisions. We sequenced whole exomes RNA from 101 tumors matched noncancer control Korean samples. used information to...
Neutrophils play a role in xenograft rejection. When neutrophils are stimulated, they eject the DNA-histone complex into extracellular space, called neutrophil traps (NET). We investigated whether NET formation actively occurs and contributes to coagulation endothelial activation.Human whole blood was incubated with porcine aortic cells (pEC) from wild-type or α1,3-galactosyltransferase gene-knockout (GTKO) pigs. In supernatant plasma human blood, level of measured by ELISA, thrombin...
<p>Table S3 shows the Multivariable Cox Regression analysis of overall (A) and progression free survival (B) using CRP Ferritin risk categories</p>
<p>Figure S1 shows the serum markers associated with severe CRS and ICANS</p>
<p>Table S2 shows Multivariable analysis of grade >2 ICANS across the three risk groups.</p>
<p>Figure S3 shows that prophylactic steroids do not improve efficacy outcomes in high risk patients</p>
<p>Figure S2 shows the optimal CRP (A) and ferritin (B) cut offs for overall survival</p>
<p>Table S6: Clinical outcomes of high-risk patients</p>
<p>Figure S3 shows that prophylactic steroids do not improve efficacy outcomes in high risk patients</p>